KNSA icon

Kiniksa Pharmaceuticals

29.02 USD
+0.18
0.62%
At close Jul 18, 4:00 PM EDT
After hours
29.02
+0.00
0.00%
1 day
0.62%
5 days
2.69%
1 month
3.90%
3 months
44.74%
6 months
55.10%
Year to date
45.54%
1 year
37.15%
5 years
21.52%
10 years
49.05%
 

About: Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.

Employees: 315

0
Funds holding %
of 7,321 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

100% more funds holding in top 10

Funds holding in top 10: 1 [Q4 2024] → 2 (+1) [Q1 2025]

100% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 18

15% more capital invested

Capital invested by funds: $772M [Q4 2024] → $888M (+$116M) [Q1 2025]

10% more funds holding

Funds holding: 159 [Q4 2024] → 175 (+16) [Q1 2025]

1.23% more ownership

Funds ownership: 93.91% [Q4 2024] → 95.15% (+1.23%) [Q1 2025]

6% more call options, than puts

Call options by funds: $2.7M | Put options by funds: $2.55M

4% more repeat investments, than reductions

Existing positions increased: 59 | Existing positions reduced: 57

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$42
45%
upside
Avg. target
$44
50%
upside
High target
$45
55%
upside

2 analyst ratings

positive
100%
neutral
0%
negative
0%
Wells Fargo
Eva Fortea Verdejo
45%upside
$42
Overweight
Maintained
9 Jul 2025
Jefferies
Roger Song
55%upside
$45
Buy
Maintained
29 Apr 2025

Financial journalist opinion

Based on 3 articles about KNSA published over the past 30 days

Positive
The Motley Fool
2 weeks ago
Kiniksa Pharmaceuticals: A 7.9 Score and Room for Growth
Explore the exciting world of Kiniksa Pharmaceuticals (KNSA 0.99%) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!
Kiniksa Pharmaceuticals: A 7.9 Score and Room for Growth
Positive
Zacks Investment Research
2 weeks ago
5 Biotech Stocks to Buy in 2025 Amid Uncertain Macroenvironment
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position EXEL, VRNA, ALKS, KNSA and IMCR well in this volatile sector.
5 Biotech Stocks to Buy in 2025 Amid Uncertain Macroenvironment
Positive
Investors Business Daily
2 weeks ago
Heart Drug Stock Rockets 20% On Sales, Boosts Outlook; Regeneron Pharma's Global Partnership Is Strong Tailwind
Biotech stock Kiniksa soared after first-quarter results on April 29. Shares are near a buy point of 28.15.
Heart Drug Stock Rockets 20% On Sales, Boosts Outlook; Regeneron Pharma's Global Partnership Is Strong Tailwind
Positive
Seeking Alpha
1 month ago
Kiniksa Pharmaceuticals: Arcalyst Performs, KPL-387 Advancing Fast
Kiniksa Pharmaceuticals has delivered strong share price performance this year thanks to a strong start to the year for Arcalyst. Medicare redesign with improved patient affordability has boosted Arcalyst's sales and 2025 outlook. I expect a beat-and-raise 2025 with Arcalyst net sales reaching or exceeding $620 million.
Kiniksa Pharmaceuticals: Arcalyst Performs, KPL-387 Advancing Fast
Neutral
GlobeNewsWire
1 month ago
Kiniksa Pharmaceuticals Announces Trial Design of Planned Phase 2/3 Clinical Trial of KPL-387 in Recurrent Pericarditis
– KPL-387 Phase 2/3 trial on track to initiate in mid-2025; Phase 2 data expected in 2H 2026 – – KPL-387 Phase 1 single ascending dose data support profile for monthly dosing – – Presentation and webcast at Jefferies 2025 Global Healthcare Conference scheduled for 12:50 pm ET today–
Kiniksa Pharmaceuticals Announces Trial Design of Planned Phase 2/3 Clinical Trial of KPL-387 in Recurrent Pericarditis
Neutral
GlobeNewsWire
1 month ago
Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences
LONDON, May 29, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will present at the following investor conferences in June:
Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences
Positive
Seeking Alpha
2 months ago
Kiniksa Pharmaceuticals: Making Steady Progress
Kiniksa Pharmaceuticals posted strong Q1 results last week, beating expectations and raising 2025 ARCALYST net sales guidance to $590-$605 million, up from $560-$580 million. Analyst firms are optimistic, with firms like Goldman Sachs, Wedbush, and Jefferies assigning Buy ratings and price targets ranging from $32 to $45 on the shares. Kiniksa also has a solid balance sheet with nearly $270 million in cash and no long-term debt.
Kiniksa Pharmaceuticals: Making Steady Progress
Neutral
GlobeNewsWire
2 months ago
Kiniksa Pharmaceuticals Announces GRAMMY® Award-Winning Country Star, Carly Pearce, Joins the Life DisRPted™ Campaign, Adding to Voices Advocating for Awareness of Recurrent Pericarditis
– Pearce joins NHL Hall-of-Famer, Henrik Lundqvist, to educate patients and caregivers about the importance of accurate and early diagnosis of recurrent pericarditis, a chronic autoinflammatory disease of the heart that is often underdiagnosed or misdiagnosed –
Kiniksa Pharmaceuticals Announces GRAMMY® Award-Winning Country Star, Carly Pearce, Joins the Life DisRPted™ Campaign, Adding to Voices Advocating for Awareness of Recurrent Pericarditis
Neutral
Seeking Alpha
2 months ago
Kiniksa Pharmaceuticals International, plc (KNSA) Q1 2025 Earnings Call Transcript
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA ) Q1 2025 Results Conference Call April 29, 2025 8:30 AM ET Company Participants Jonathan Kirshenbaum - Investor Relations Sanj Patel - Chairman & Chief Executive Officer Ross Moat - Chief Commercial Officer Mark Ragosa - Chief Financial Officer John Paolini - Chief Medical Officer Conference Call Participants Mary Kate - Citi Roger Song - Jefferies Eva Fortea-Verdejo - Wells Fargo Anupam Rama - JPMorgan David Nierengarten - Wedbush Operator Good day, and thank you for standing by. Welcome to the Kiniksa Pharmaceuticals First Quarter 2025 Earnings Conference Call.
Kiniksa Pharmaceuticals International, plc (KNSA) Q1 2025 Earnings Call Transcript
Positive
Zacks Investment Research
2 months ago
Kiniksa Pharmaceuticals, Ltd. (KNSA) Tops Q1 Earnings and Revenue Estimates
Kiniksa Pharmaceuticals, Ltd. (KNSA) came out with quarterly earnings of $0.11 per share, beating the Zacks Consensus Estimate of $0.02 per share.
Kiniksa Pharmaceuticals, Ltd. (KNSA) Tops Q1 Earnings and Revenue Estimates
Charts implemented using Lightweight Charts™